225 related articles for article (PubMed ID: 30689946)
1. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.
Bestgen B; Kufareva I; Seetoh W; Abell C; Hartmann RW; Abagyan R; Le Borgne M; Filhol O; Cochet C; Lomberget T; Engel M
J Med Chem; 2019 Feb; 62(4):1817-1836. PubMed ID: 30689946
[TBL] [Abstract][Full Text] [Related]
2. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
[TBL] [Abstract][Full Text] [Related]
3. Identification and Biological Evaluation of CK2 Allosteric Fragments through Structure-Based Virtual Screening.
Li C; Zhang X; Zhang N; Zhou Y; Sun G; Zhao L; Zhong R
Molecules; 2020 Jan; 25(1):. PubMed ID: 31935979
[TBL] [Abstract][Full Text] [Related]
4. Structural and Mechanistic Basis of the Inhibitory Potency of Selected 2-Aminothiazole Compounds on Protein Kinase CK2.
Lindenblatt D; Nickelsen A; Applegate VM; Jose J; Niefind K
J Med Chem; 2020 Jul; 63(14):7766-7772. PubMed ID: 32589844
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship study of 4-(thiazol-5-yl)benzoic acid derivatives as potent protein kinase CK2 inhibitors.
Ohno H; Minamiguchi D; Nakamura S; Shu K; Okazaki S; Honda M; Misu R; Moriwaki H; Nakanishi S; Oishi S; Kinoshita T; Nakanishi I; Fujii N
Bioorg Med Chem; 2016 Mar; 24(5):1136-41. PubMed ID: 26850376
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
8. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Impact of Linker Flexibility and Fragment Ionization on the Design of CK2 Allosteric Inhibitors: Comparative Molecular Dynamics Simulation Studies.
Zhou Y; Zhang N; Qi X; Tang S; Sun G; Zhao L; Zhong R; Peng Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301250
[TBL] [Abstract][Full Text] [Related]
11. A Selective Biligand Inhibitor of CK2 Increases Caspase-3 Activity in Cancer Cells and Inhibits Platelet Aggregation.
Rahnel H; Viht K; Lavogina D; Mazina O; Haljasorg T; Enkvist E; Uri A
ChemMedChem; 2017 Oct; 12(20):1723-1736. PubMed ID: 28837260
[TBL] [Abstract][Full Text] [Related]
12. The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules.
Raaf J; Brunstein E; Issinger OG; Niefind K
Chem Biol; 2008 Feb; 15(2):111-7. PubMed ID: 18291315
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
Ostrynska OV; Balanda AO; Bdzhola VG; Golub AG; Kotey IM; Kukharenko OP; Gryshchenko AA; Briukhovetska NV; Yarmoluk SM
Eur J Med Chem; 2016 Jun; 115():148-60. PubMed ID: 27017545
[TBL] [Abstract][Full Text] [Related]
14. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
15. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 2,6-di(furan-3-yl)anthracene-9, 10-dione as an inhibitor of human protein kinase CK2.
Haidar S; Meyers A; Bollacke A; Jose J
Pharmazie; 2015 Dec; 70(12):772-6. PubMed ID: 26817273
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
18. Thiazole- and selenazole-comprising high-affinity inhibitors possess bright microsecond-scale photoluminescence in complex with protein kinase CK2.
Vahter J; Viht K; Uri A; Manoharan GB; Enkvist E
Bioorg Med Chem; 2018 Oct; 26(18):5062-5068. PubMed ID: 30217463
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of novel chiral TBBt derivatives with hydroxyl moiety. Studies on inhibition of human protein kinase CK2α and cytotoxicity properties.
Borowiecki P; Wawro AM; Wińska P; Wielechowska M; Bretner M
Eur J Med Chem; 2014 Sep; 84():364-74. PubMed ID: 25036794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
